Allogeneic Anti-TROP2-CAR-IL-15-transduced TGFBR2-knockout Cord Blood-derived Natural Killer Cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; tumor-associated calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) and expressing the cytokine interleukin-15 (IL-15) and in which the gene transforming growth factor-beta receptor II (TGFbRII; TGFBR2) is deleted, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-TROP2-CAR-IL-15-transduced TGFBR2-KO CB-derived NK cells target, bind to and induce selective cytotoxicity in TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival. IL-15 is a pro-survival cytokine that promotes the persistence of multiple lymphocyte lineages and potentiates the immune response against tumor cells. As TGF-beta activation and release leads to NK cell inactivation, deletion of the TGFBR2 gene increases the potency, persistence and efficacy of the NK cells and enhances anti-tumor activity.

**Synonyms:** - Allogeneic Anti-TROP2-CAR-IL-15-transduced TGFBR2-KO CB-derived NK Cells - Allogeneic Anti-TROP2-CAR-IL-15-transduced TGFBR2-KO CB-derived NKs - Allogeneic Anti-TROP2-CAR-IL-15-transduced TGFbRII-KO CB-derived NK Cells - Allogeneic IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells - Allogeneic IL-15-transduced TGFBR2-KO Anti-TROP2 CAR-NK Cells - Allogeneic TROP2 CAR/IL-15 TGFBR2 KO NK Cells